Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma
Andrea Vallés‐Martí(Dutch Cancer Society), Connie R. Jiménez(Amsterdam University Medical Centers)
Cited by 26
Related Papers
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines
|Molecular & Cellular Proteomics|2020|46
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues
|Molecular Oncology|2024|9
Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines
|Molecular & Cellular Proteomics|2022|5
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active phosphokinases
|bioRxiv (Cold Spring Harbor Laboratory)|2018|3